Preclinical Efficacy of Silicon-based Dual Energy CT Contrast Material
Preclinical Efficacy of Silicon-based Dual Energy CT Contrast Material
批准号:
8833135
负责人:
William Guerin Bradley
金额:
$23.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-16 至 2016-08-31
关键词:
AbdomenAbscessAdoptedAmericanAnatomyAnimal ModelAttenuatedBariumBiocompatibleBlood VesselsCalculiClinicalColorComplexContrast MediaCost SavingsDataDevelopmentDiagnosisDiagnosticDiagnostic ErrorsDiseaseDoseDrug FormulationsDrug KineticsEffectivenessEmergency SituationEnteralFDA approvedFoundationsGastrointestinal DiseasesGoalsHeadHealth Care CostsHealthcare SystemsHemorrhageImageIn VitroIndividualInflammatoryIntestinesIntravenousIodineIschemiaLow Dose RadiationMeasuresMedicalMedical ErrorsOralOrangesOrganOutcomePhasePolymersPreclinical TestingPropertyProtocols documentationRadiationRattusResearchResolutionRoentgen RaysRouteRuptureSafetyScanningSeriesSignal TransductionSiliconSiliconesSmall Business Technology Transfer ResearchSpeedTestingTomography, Computed, ScannersToxic effectTraumaX-Ray Computed Tomographyabsorptionbasecommercializationcostdrug developmenthigh riskimprovedin vivonovelpre-clinicalpreclinical efficacypreclinical evaluationpublic health relevanceradiologistsoft tissueuptake
中文摘要
描述(申请人提供):我们的长期目标是彻底改变数百万美国人在各种胃肠道疾病中使用计算机断层扫描(CT)成像的安全性和有效性。肠道和静脉造影剂可改善腹部疾病的CT成像。不幸的是,目前的临床造影剂没有一种在成像方面与其他材料有明显的不同,甚至在现代双能CT(DECT)扫描仪上也是如此,因为所有的造影剂都是以碘或钡为基础的,它们在不同的X射线谱上以类似的方式衰减X射线。这一限制导致了模糊的图像,在美国每年造成超过20亿美元的医疗差错。我们现在有戏剧性的临床前活体数据表明,新型口腔硅胶材料可以同时给药,但很容易与目前的碘化静脉制剂区分开来,在DECT扫描仪的一次通过中就能同时产生高分辨率、完美配准的肠道和血管的CT图像。这种双对比增强的DECT扫描以比传统CT扫描更低的辐射剂量提供丰富的腹部解剖细节,消除了方案错误,提高了诊断速度,并将显著降低医疗保健成本。我们的试剂是颠覆性的,因为硅胶以前没有被描述为CT造影剂的X射线衰减材料。由于DECT扫描仪已经在临床上使用,传统的肠道造影剂已经广泛使用,一旦FDA批准,一种显著改进的硅胶肠道造影剂应该会被迅速采用。我们的总体假设是,一种新型的硅胶造影剂是安全的,减少了辐射剂量,并在一次DECT扫描中提供了常规CT造影剂无法实现的丰富详细的解剖图像。我们项目的具体目的是检验以下假设:1)硅酮造影剂的全身摄取极少;2)有机硅造影剂和自动曝光控制获得的CT扫描所需的辐射剂量比传统的肠道造影剂更小;3)在体内外,用肠道CT造影剂和静脉碘化造影剂获得的DECT能提供更多关于造影剂浓度和分布的信息。这些关键数据将成为后续开发这种强大的DECT试剂的基础,以催化CT成像的帧转换,从而提高日常腹部场景的CT成像诊断的速度、准确性和信心,同时降低医疗系统的成本和辐射剂量。
英文摘要
DESCRIPTION (provided by applicant): Our long term goal is to revolutionize the safety and effectiveness of computed tomography (CT) imaging for millions of Americans across a broad range of gastrointestinal disease. Bowel and intravenous contrast materials improve the CT imaging of abdominal disease. Unfortunately, none of the current clinical contrast materials are visibly different from the others at imaging, even on modern dual energy CT (DECT) scanners, because all agents are based on iodine or barium which attenuate X-rays similarly across different X-ray spectra. This limitation leads to ambiguous images that cost over $2B in medical errors annually in the USA. We now have dramatic preclinical in vivo data showing that novel oral silicone materials can be delivered concurrently with yet be easily differentiated from current iodinated intravenous agents to produce simultaneous, high-resolution, perfectly co-registered CT images of the bowel and vasculature in a single pass of the DECT scanner. Such double contrast-enhanced DECT scans give rich abdominal anatomic detail at lower radiation dose than a conventional CT scan, eliminate protocol errors, increase the speed of diagnosis, and will dramatically reduce health care costs. Our agent is disruptive because silicone has not previously been described as an X-ray attenuating material for CT contrast agents. Since DECT scanners are already clinically available and conventional enteric contrast is already widely used, a dramatically improved silicone enteric contrast should be rapidly adopted once FDA approved. Our overall hypothesis is that a novel silicone contrast agent is safe, reduces radiation dose, and provides richly detailed anatomic images in a single DECT scan that cannot be achieved with conventional CT contrast agents. The Specific Aims of our project are to test the hypotheses that 1) Enteric silicone contrast agents show minimal if any systemic uptake; 2) CT scans obtained with enteric silicone-based contrast material and automated exposure control require less radiation dose than with conventional enteric contrast agents; 3) DECT obtained with enteric CT contrast and intravenous iodinated contrast provide substantially more information on contrast material concentration and distribution than when obtained with conventional barium and iodinated agents in vitro and in vivo. These key data will be the foundation for subsequent development of this powerful DECT agent to catalyze a frame-shift in CT imaging that will increase the speed, accuracy, and confidence of CT imaging diagnosis for everyday abdominal scenarios with reduced cost to the healthcare system and lower radiation dose.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
海外基金